

# Obesity and chronic kidney disease

G. Eknoyan

Renal Section, Department of Medicine. Baylor College of Medicine. Houston, Texas (USA)

Nefrologia 2011;31(4):397-403

doi:10.3265/Nefrologia.pre2011.May.10963

## ABSTRACT

Obesity is associated with the early onset of glomerulomegaly, hemodynamic changes of a hyperfiltering kidney, and increased albuminuria, which are potentially reversible with weight loss. However, pathologic lesions of focal segmental glomerulosclerosis develop in experimental models of sustained obesity, and are observed in morbidly obese humans presenting with massive proteinuria. In addition, several observational, cross sectional and longitudinal studies document that obesity is as an independent risk factor for the onset, aggravated course, and poor outcomes of chronic kidney disease, even after adjustment for confounding comorbidities including metabolic syndrome, diabetes and hypertension, the major causes of chronic kidney disease. Early dietary intervention to reduce weight, and where necessary bariatric surgery, should be considered in the management of overweight and obese chronic kidney disease (CKD) patients.

**Keyw ords:** Obesity. Kidney disease. Diabetes. Albuminuria. Hypertension.

## INTRODUCTION

Throughout most of human history corpulence has been considered a sign of good health and being fat an advantage. The potential of harmful effects of excess body weight were appreciated in the 19<sup>th</sup> century, but it is only in the early decades of the 20<sup>th</sup> century that the complications and increased morbidity and mortality of obesity began to be documented<sup>1</sup>. Since then, the accrued evidence clearly indicates that fat cells provide not merely energy storage but that components of excess adipose tissue function as an

## Obesidad y enfermedad renal crónica

### RESUMEN

*La obesidad está relacionada con la aparición temprana de glomerulomegalia, las alteraciones hemodinámicas del riñón hiperfiltrante y el aumento de la albuminuria, síntomas que son reversibles con una pérdida de peso. Por el contrario, las lesiones patológicas de la glomeruloesclerosis focal y segmentaria se desarrollan en modelos experimentales de obesidad mantenida y se observan en pacientes con obesidad mórbida que presentan proteinuria masiva. Además, diferentes estudios observacionales, transversales y longitudinales han demostrado que la obesidad supone un factor de riesgo independiente de la aparición, el empeoramiento, y la escasa respuesta al tratamiento de la enfermedad renal crónica (ERC), incluso después de ajustar por variables de confusión, incluido el síndrome metabólico, la diabetes y la hipertensión, las principales causas de la enfermedad renal crónica. En los pacientes con enfermedad renal crónica que presentan sobrepeso y obesidad debe considerarse la instauración precoz de una dieta para reducir peso y la cirugía bariátrica, en caso de ser necesaria.*

**Palabras clave:** Obesidad. Enfermedad renal. Diabetes. Albuminuria. Hipertensión.

endocrine organ with multiple detrimental health consequences, and that obesity frequently contributes to the pathogenesis, complicates the course, and increases the risk of several diseases including diabetes, hypertension, cardiovascular disease, metabolic syndrome, certain malignancies, and kidney disease (Table 1)<sup>2,3</sup>. The importance and urgency of identifying the detrimental consequences of obesity has been the dramatic increase in its incidence and prevalence after the Second World War. Population surveys indicate that two thirds of United States adults are overweight and one third obese<sup>4,5</sup>. Similar trends documented in other parts of the world have led to the identification of obesity as a worldwide public health problem of epidemic proportions with increasing incidence, high costs, and poor outcomes<sup>1-6</sup>.

**Correspondence:** Garabed Eknoyan  
Renal Section. Department of Medicine.  
Baylor College of Medicine. One Baylor Plaza,  
TX 77030, Houston. Texas. USA.  
geknoyan@bcm.edu

**Table 1.** Co-morbidities associated with overweight and obesity

1. Diabetes
2. Hypertension
3. Metabolic syndrome
4. Cardiovascular disease
5. Cancer
6. Osteoarthritis
7. Gall bladder disease
8. Non-alcoholic liver disease
9. Pancreatitis
10. Obstructive sleep apnea
11. Depression
12. Chronic kidney disease

The first renal complication to be associated with obesity was renal cell carcinoma<sup>7</sup>. The effects of obesity on kidney function and disease have since been identified and become a subject of increased study and concern<sup>8-12</sup>. Actually, an effect of obesity on albuminuria and blood pressure in kidney disease was reported as early as 1923<sup>13</sup>, when actuarial data first began to identify overweight as a risk factor for mortality, but were forgotten or neglected when cardiovascular mortality emerged as the principal cause of obesity-related mortality<sup>1</sup>. Based on a meta-analysis, it has been estimated that the presence of kidney disease is related to overweight (BMI = 25-29.9) and obesity (BMI ≥30)<sup>14</sup>. An association between obesity and kidney disease could be made in 24.2% of males and 33.9% of females in the U.S., and in industrialized countries in 13.8% of men and 24.9% of women. Furthermore, obesity was shown to adversely affect the progressive loss of kidney function among those with chronic kidney disease (CKD)<sup>14</sup>. Regrettably, the detrimental renal effects of obesity remain unrecognized and are not included in major reviews of obesity<sup>3</sup>.

This article reports the effects of obesity on the normal and diseased kidney (Table 2), considers the factors implicated in their pathogenesis, and presents an approach to their management.

### EFFECTS OF OBESITY ON RENAL HEMODYNAMICS

Experimental studies in genetically obese rats and force fed dogs show an early onset of hemodynamic changes in kidney function characterized by an increase in glomerular filtration rate (GFR) and effective plasma blood flow, accompanied by variable increments in filtration fraction and albumin excretion<sup>15,16</sup>. These early changes are reversible as shown in studies of hyperphagic obese Zucker rats in which, early (at 6 or 12 weeks of age) but not late (after 26 weeks of age), food restriction was associated with reversal of glomerular hyperfiltration and albuminuria<sup>17</sup>.

Cross sectional and longitudinal clinical studies confirm these hemodynamic changes characteristic of a hyperfiltering glomerulus in humans, whose first clinical manifestation of renal injury appears to be increased albuminuria<sup>18,19</sup>. Compared to lean subjects, in severely obese individuals the GFR and renal plasma flow were shown to be higher by 51 and 31 percent, respectively<sup>20</sup>. Glomerular macromolecular sieving studies in these individuals indicate that a principal reason for these hemodynamic effects and attendant increase in glomerular filtration fraction is due to afferent arteriolar dilatation. An added contributory role of efferent arteriolar vasoconstriction on the increased filtration fraction, due to stimulation of the renin-angiotensin system, has been documented also and is supported by the salutary effect of angiotensin receptor blocking drugs on the albuminuria and renal hemodynamics in experimental and clinical studies of obesity<sup>21,22</sup>. Evidence also exists for a role of obesity-induced increase in renal sympathetic tone that could contribute and aggravate these hemodynamic changes<sup>23,24</sup>.

A significant correlation between increased urinary albumin excretion and body weight has been shown in both non-diabetic and diabetic overweight individuals<sup>19,25-27</sup>. The effect of obesity on proteinuria is not bimodal, but a continuum that is directly related to increasing body mass index (BMI). In a retrospective analysis of the database of a population

**Table 2.** Effects of overweight and obesity on the kidney

#### Hemodynamic

- ↑ Effective plasma flow
- ↑ Glomerular filtration rate
- ↑ Glomerular filtration fraction
- ↑ Albuminuria

#### Structural

- ↑ Kidney weight
- ↑ Glomerular planar surface
- Mesangial expansion
- Podocyte injury

#### Pathologic

- Glomerulomegaly
- Glomerulosclerosis
- Obesity related glomerulopathy

#### Chronic kidney disease

- ↑ Onset of kidney disease
- ↑ Progression to kidney failure
- ↑ Proteinuria

#### End-stage renal disease

- ↑ Incidence and prevalence
- Survival advantage in hemodialysis
- ↑ Graft loss in kidney transplant recipients

#### Other

- ↑ Renal cell carcinoma
- ↑ Nephrolithiasis

study on the impact of microalbuminuria on renal and cardiovascular risk, the prevalence of microalbuminuria (30-300 mg/d) in men increased from 9.5% in those with normal body weight (BMI <25) to 18.3% in those who were overweight, and to 29.3% in those who were obese; in women, the respective percentages were 6.6%, 9.2%, and 16.0%<sup>26</sup>.

The hemodynamic effects of overweight on kidney function and albuminuria are magnified in the presence of hypertension, which itself is a clinical complication of obesity<sup>10,19,28</sup>. A similar amplifier effect of obesity has been reported in overweight diabetics<sup>27</sup>. In a cross-sectional study of risk factors for microalbuminuria among African Americans with newly diagnosed type 2 diabetes, 23.4% of whom had microalbuminuria, the urine albumin to creatinine ratio was independently associated with BMI<sup>27</sup>. Importantly, moderate weight reduction (4.1%) in overweight diabetics who were proteinuric decreased their proteinuria by about 30%<sup>29</sup>. There is now convincing evidence of a salutary effect of weight reduction, by bariatric surgery or dietary caloric restriction, on the proteinuria of obese individuals<sup>30,31</sup>.

In evaluating kidney function in obese individuals, it is important to note that currently available methods of estimated GFR (eGFR) were derived in lean individuals; both the Cockcroft-Gault formula and the MDRD equation are less accurate in malnourished as well as obese individuals. The Cockcroft-Gault formula grossly overestimates eGFR and should not be used in obese individuals. The MDRD equation appears to be more dependable in obesity, but also tends to err by 10 ml/min/1.73 m<sup>2</sup> or more in obese cases<sup>32,33</sup>.

### EFFECTS OF OBESITY ON RENAL MORPHOLOGY AND PATHOLOGY

In force-fed dog studies, the hemodynamic changes of obesity were associated with an increase in kidney weight of about 40%<sup>10,15</sup>. This was accompanied by an increase of glomerular size together with podocyte injury and expansion of the mesangium, and in sustained obesity resulted in mesangial sclerosis<sup>15</sup>. As with the hemodynamic changes, these early structural changes of obesity were prevented by dietary restriction in hyperphagic Zucker rats<sup>16</sup>.

In humans, despite the occurrence of glomerulomegaly, hyperfiltration, and albuminuria most obese individuals do not develop glomerulosclerosis<sup>34</sup>. In a study comparing kidney biopsies from obese to lean living kidney donors the glomerular planar surface area was significantly greater in those who were obese but showed no evidence of glomerulosclerosis<sup>18</sup>. However, cases of glomerulomegaly, focal segmental glomerulosclerosis, proteinuria, and decreased kidney function do occur in obesity, a clinicopathological entity that has been termed obesity-related glomerulopathy<sup>35</sup>. The increased prevalence of obesity appears to be reflected in an increased incidence of obesity-related glomerulopathy, as shown in a

retrospective analysis of kidney biopsies at one center that revealed a 10-fold increase in its occurrence over the 15 year period of the study<sup>36</sup>. The occurrence of glomerulosclerosis only in selected cases of obesity may be related to genetic predisposition, the presence of other co-existent risk factors, and the severity and duration of obesity.

Clinically, obesity-related glomerulopathy is associated with proteinuria and was first described in 1974 in four morbidly obese patients (BMI >50 kg/m<sup>2</sup>) who presented with nephrotic syndrome, none of whom were diabetic and only two were hypertensive<sup>37</sup>. Kidney biopsies on two of them revealed focal and segmental glomerulosclerosis. In all four cases the proteinuria decreased during dietary-induced weight loss. Nephrotic range proteinuria has been reported also in severe obesity with normal kidney biopsy<sup>38</sup>. Reduction of nephrotic range proteinuria in obese diabetics occurs with weight loss after gastric bypass surgery<sup>39,40</sup>. In morbidly obese individuals who develop non-nephrotic range albuminuria, the histologic changes appear to precede the onset of microalbuminuria, and the onset of proteinuria precedes the decline in GFR by several years<sup>41</sup>.

The long term prognosis of obesity-related glomerulopathy is poor, but unlike idiopathic focal segmental sclerosis, in obesity-related glomerulopathy the incidence of nephrotic range proteinuria is lower, the serum albumin higher, the serum cholesterol lower, the edema less severe, and the progression to end-stage renal disease slower<sup>34,42</sup>.

### EFFECT OF OBESITY ON PROGRESSION OF KIDNEY DISEASE

In population based epidemiologic studies, obesity has been shown to be associated with new onset of CKD and increased rate of progression to kidney failure in individuals with existing primary kidney disease<sup>8-12</sup>. In a study of predictors of new onset kidney disease, in a cohort of 2585 patients followed for 20 years, the odds ratio for new onset of chronic kidney disease was 1.23 per one standard increase in BMI<sup>43</sup>. Increased BMI has also been shown to increase the risk of progression of existing kidney disease, adjusted for confounders including diabetes and hypertension. Obese individuals with CKD have a higher rate of decline in glomerular filtration rate and progress faster to end-stage renal disease (ESRD)<sup>44</sup>. In a large population study evaluating the risk for ESRD over a span of 20 years, increased BMI was an independent risk factor for progression to ESRD in obese individuals compared to those with normal body weight<sup>45</sup>. In another population-based case controlled study, a BMI of over 25 at age 20 was associated with a threefold increased risk for developing new onset of kidney disease, even after correction for hypertension and diabetes<sup>46</sup>. The coexistence of diabetes and obesity in this study doubled the risk for new onset of kidney disease.

Direct evidence for a detrimental effect of obesity on kidney disease comes from the study of specific diseases such as IgA nephritis, where excessive body weight (BMI  $\geq 25$ ) at the time of kidney biopsy was shown to be associated with the severity of the detected pathologic lesions, the subsequent rate of loss of kidney function, and to be an independent risk factor for progression to ESRD<sup>41,47</sup>. Similar results have been observed on the onset of proteinuria and progressive loss of kidney function after unilateral nephrectomy in obese individuals<sup>48</sup>. At the 20-year follow up of this study, most of the normal non-obese individuals had normal kidney function as compared to only about 40% of the expected GFR for age in the obese subjects. These observations are more dramatically evident in kidney transplant recipients. In an analysis of a large registry database (51927 kidney transplant recipients), it was shown that the relative risk of graft loss, patient death, and cardiovascular mortality increased<sup>49</sup> by 20-40% at increasing BMIs of over 30 kg/m<sup>2</sup>. As a result, a BMI of over 35 kg/m<sup>2</sup> has come to be considered a contraindication to kidney transplantation in some centers.

The detrimental effect of overweight on the course of CKD is supported by several epidemiologic studies that show a higher prevalence and increasing incidence of obesity in patients with ESRD being initiated on dialysis<sup>50</sup>. In a study of over 300,000 subjects, the presence of obesity was shown to increase the relative risk of ESRD, adjusted for confounding factors<sup>45</sup>. Once again, this relationship was not related to obesity bi-modally, but showed an incremental continuum related to increased BMI that was statistically significant at BMI values of  $>25$ . Compared to lean subjects, the relative risk of ESRD was 3.57 for those with a BMI of 30-34.9, 6.12 for those with a BMI of 35-39.9, and 7.07 for those with morbid obesity (BMI  $>40$ )<sup>45</sup>.

### EFFECT OF OBESITY IN CHRONIC AND ACUTE DIALYSIS PATIENTS

Contrary to the convincing evidence of a detrimental effect of obesity on the onset, course, and outcomes of CKD, obesity in dialysis patients appears to provide a survival advantage, an effect that has been dubbed “reverse epidemiology”<sup>51</sup>. This striking disparity with the usual detrimental effects of obesity on survival in CKD may be due to the relatively higher mortality of chronic kidney disease patients during the progression of their disease with only those having inherent survival advantages progressing to ESRD, and the fact that the initial reported analysis compared variable survival data (10 years for normal, 4 years in dialyzed patients). In a study in which subjects were followed for a comparable period, obesity was shown actually to increase mortality in dialysis patients<sup>52</sup>.

Another reason for an advantage of obesity in dialyzed patients may be teleological. The genetic origins of obesity rooted in the survival advantage it provided at times of famine may be operative in ESRD patients on dialysis.

Maintenance hemodialysis is essentially a catabolic state similar to malnutrition in which obesity may convey some survival advantage to dialysis patients, much like it did to their ancestral hunters-gatherers at times of food scarcity<sup>1,53</sup>. The survival advantage proffered by obesity is not limited to dialyzed patients but is also observed in other chronic diseases such as congestive heart failure, liver cirrhosis, and obstructive pulmonary disease<sup>3,6,54</sup>.

Relevant to this issue is the finding that obesity also confers survival advantage in intensive care unit (ICU) patients requiring renal replacement therapy<sup>54</sup>. As in the case of CKD, obesity was an independent risk factor for developing acute kidney injury in the ICU, but conveyed improved survival in those requiring dialysis.

### OTHER EFFECTS OF OBESITY ON THE KIDNEY


Obesity is associated with an increased risk for renal cell carcinoma<sup>7</sup>. Past cautiousness in considering this as the only renal complication of obesity likely reflects the fact that the renal complications of obesity were initially attributed to be secondary to the common association of obesity with hypertension and diabetes, the two most common causes of chronic kidney disease<sup>6</sup>. An improper caution refuted by the data reviewed here, but an error that regrettably continues to be perpetuated in the current literature<sup>3</sup>.

Actually, the relationships between obesity, hypertension, diabetes, cardiovascular disease, metabolic syndrome and CKD can be viewed as the clinical intersection of a cluster of diseases that are associated with kidney disease (Figure 1). The coexistence of obesity in any of these diseases (diabetes, hypertension, metabolic syndrome, cardiovascular disease) magnifies the risk of onset of kidney disease and its progression to ESRD. Conversely, the coexistence of obesity and chronic kidney disease in any of those other diseases increases their risk of morbidity and mortality<sup>6</sup>.

### OBESITY, DIABETES, AND THE KIDNEY

Whereas thermodynamic studies clearly establish fat deposition as a consequence of imbalance between the energy derived from ingested food and that of energy expended in the course of daily activities, obesity is in fact a multifactorial disease in which the adipose tissue rather than just being a site for excess energy storage actually functions as an endocrine and exocrine organ with neurohumoral and vasoactive effects that are implicated in the genesis of obesity-related organ damage including the kidney (Table 3). In addition to angiotensinogen and renin, adipose tissue produces several cytokines, growth factors, and bioactive adipokines that have been implicated in or associated with kidney injury<sup>13,53-63</sup>.





**Figure 1.** The cluster of co-morbidities associated with and aggravated by obesity. Where there is clinical intersection of a given circle with that of obesity, the co-existence of obesity emerges as a risk multiplier of the outcomes of that disorder. The areas where there is an overlap of more than one circle the risks are further magnified.

Among the commonly implicated mechanisms of organ damage is that of insulin resistance that characterizes the obese and type II diabetics<sup>58</sup>, and may account for the hemodynamic disorders of obesity-related hyperfiltration, glomerulomegaly, and albuminuria that are also the characteristics of early diabetic nephropathy. Although an association between microalbuminuria and BMI is a feature of non-diabetic obese subjects, in clinical studies of diabetics it is rather difficult to separate the effects of increased BMI alone from its concomitant effects on glycemic control<sup>27</sup>. However, the lesions of obesity-related glomerulopathy are distinctly different from those of diabetic nephropathy<sup>6</sup>. The characteristic lesions of nodular sclerosis and membranous thickening of diabetic nephropathy are not observed in the classic lesions of obesity-related glomerulopathy, which is one of focal segmental glomerulosclerosis. In a study comparing the kidney biopsies of microalbuminuric diabetic subjects, there was no difference in glomerular pathology of obese compared to lean diabetics who were biopsied<sup>64</sup>. The severe hyperglycemia and advanced glycosylated end products (AGE) in diabetes have been incriminated for these structural differences, but remain to be proven. Thus, whereas obesity per se results in distinct hemodynamic, structural, and pathologic changes in the kidney, in addition it is an independent amplifier of the risk associated with CKD in general and with diabetic nephropathy, in particular (Figure 1).

**Table 3.** Factors implicated in the pathogenesis of CKD in obesity

↑ Renin angiotensin system
↑ Aldosterone
↑ Sympathetic nervous system
↑ Insulin resistance
↑ Salt intake
Altered adipokines
↑ Leptin
↑ Fetuin-A
↑ Resistin
↓ Adiponectin
↑ Tumor necrosis factor- $\alpha$
↑ Free fatty acids
↑ Endothelin-1
↓ Brain natriuretic protein
↑ Plasminogen activator inhibitor-1
Infiltrating macrophage phenotypic switch

By the same token, whereas the lesions of obesity-related glomerulopathy are similar to those of idiopathic focal segmental glomerulonephritis, there are clinical differences apart from the glomerulomegaly of obesity that distinguishes them from each other<sup>6,34</sup>. Viewed in an evolutionary framework, the millennia of human evolution during which the genetic advantages of obesity changed it from one of survival advantage to a disease after food became easily available, was accompanied by the evolution of genetically diverse populations, who are divergent in their genetic susceptibility to the consequences of diseases in general and of obesity-related renal disease in particular. This may account, at least in part, why the renal morphologic complications of obesity are encountered clinically in some but not all obese individuals, whereas its detrimental hemodynamic effects are variably expressed, in most of those with primary forms of CKD, including diabetic nephropathy. Coupled with environmental factors and other acquired life style changes (smoking, exercise, type of food) this may account for the variations in obesity-related complications in general and that of obesity-related glomerulosclerosis in particular. Obviously, there remain many gaps in our current knowledge of these effects that remain to be explored and explained.

## CONCLUSION

In summary, a growing body of evidence that is convincing in balance indicates specific hemodynamic, structural, and functional changes of the kidney in obesity, and the onset of obesity-related glomerulosclerosis in some of them. In

addition, the presence of obesity amplifies the risk for and outcomes of chronic kidney disease in diabetes, hypertension, metabolic syndrome, primary kidney diseases, and cardiovascular disease (Figure 1). Given the evidence for the potential reversibility of these detrimental obesity-related hemodynamic effects and the proteinuria of obesity on progression of kidney diseases and their outcomes, weight reduction (dietary or bariatric surgery) should be considered a component of the therapeutic regimen of all overweight individuals with CKD<sup>30,31</sup>.

Apart from caloric restriction, given the tendency to salt retention of obesity salt restriction must be part of their dietary management. In addition, because of the acid load of the high protein diet consumed by obese individuals consideration should be given to the use of bicarbonate supplementation in those with reduced kidney function<sup>65</sup>.

Also, given the increased activity of the renin-angiotensin system in obesity angiotensin converting enzyme inhibitors and angiotensin receptor blocking agents should be part of their therapeutic regimen, especially in the presence of proteinuria and hypertension<sup>6,12,34</sup>.

## REFERENCES

- Eknoyan G. A history of obesity, or how what was good became ugly and then bad. *Adv Chronic Kidney Dis* 2006;13:421-7.
- Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. *J Am Medical Assoc* 2002;288:1723-7.
- Pi-Sunyer X. The medical risks of obesity. *Postgrad Med* 2009;121:21-33.
- Yanovski SZ, Yanovski JA. Obesity prevalence in the United States—Up, down, or sideways. *N Engl J Med* 2011;364:987-9.
- Kopelman P. Health risks associated with overweight and obesity. *Obesity Rev* 2007;8(Suppl 1):13-7.
- Eknoyan G. Obesity, diabetes, and chronic kidney disease. *Curr Diabetes Rep* 2007;7:449-53.
- Pan SY, DesMeules M, Morrison H, Wen SW. Obesity, high energy intake, lack of physical activity, and the risk of kidney cancer. *Cancer Epid Biom Prev* 2006;15:2453-60.
- Praga M. Obesity—a neglected culprit in renal disease. *Nephrol Dial Transpl* 2002;17:1157-9.
- Sivestava T. Nondiabetic consequences of obesity on kidney. *Pediatr Nephrol* 2006;21:463-70.
- Rutkowski P, Klasen A, Sebekova K. Renal disease in obesity. The need for greater attention. *J Ren Nutr* 2006;16:216-33.
- Chertow GM, Hsu C, Johansen KL. The emerging body of evidence: obesity and chronic kidney disease. *J Am Soc Nephrol* 2006;17:1501-2.
- Mathew AV, Okada S, Sharma K. Obesity related kidney disease. *Curr Diabetes Rev* 2011;7:41-9.
- Preble WE. Obesity: observations on one thousand cases. *Boston Med Surg J* 1923;188:617-21.
- Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease. A systematic review and meta-analysis. *Kidney Int* 2008;73:19-33.
- O'Donnell MP, Kasiske BL, Cleary MP, Keane WF. Effects of genetic obesity on renal status and function in the Zucker rat. *J Lab Clin Med* 1985;106:605-10.
- Henegan JR, Bigler SA, Henegan LK. Functional and structural changes in the kidney in the early stages of obesity. *J Am Soc Nephrol* 2001;12:1211-7.
- Maddox DA, Alavi FK, Santella RN, Zawada ET. Prevention of obesity-linked renal disease: age dependent effect of dietary food restriction. *Kidney Int* 2002;62:208-19.
- Rea DJ, Heimbach JK, Grande JP, Textor SC, Taler SJ, Prieto M, et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. *Kidney Int* 2006;70:1636-41.
- Valensi P, Assayag M, Busby M, Pariès J, Lormeau B, Attali JR, et al. Microalbuminuria in obese patients with or without hypertension. *Int J Obesity* 1996;20:574-9.
- Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafer U. Glomerular hemodynamic in severe obesity. *Am J Physiol Renal Physiol* 2000;278:F817-F822.
- Praga M, Hernández F, Andrés A. Effects of body weight loss and captopril treatment on proteinuria associated with obesity. *Nephron* 1995;70:34-41.
- Blanco S, Bonet J, López D, Casas I, Romero R. ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. *Kidney Int* 2005;(Suppl):S10-S14.
- Esler M, Rumanti M, Weisner G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. *Am J Hypertens* 2001;14(Suppl 1):304s-309s.
- Hall JE, Kuo JJ, Silva AA, De Paula RB, Liu J, Tallam L. Obesity-associated hypertension and kidney disease. *Curr Opin Nephrol Hypertens* 2003;12:195-200.
- Savage S, Nagel NJ, Estacio RO, Lukken N, Schrier RW. Clinical factors associated with urinary albumin excretion in Type II diabetes. *Am J Kidney Dis* 1995;25:836-44.
- DeJong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL, PREVEND Study Group. Obesity and target organ damage: the kidney. *Int J Obesity* 2002;26(Suppl 4):S21-S24.
- Kohler KA, McClellan WM, Ziemer DC, Kleinbaum DG, Boring JR. Risk factors for microalbuminuria in black Americans with newly diagnosed type 2 diabetes. *Am J Kidney Dis* 2000;36:903-13.
- Toto RD, Greene T, Hebert LA. Relationship of body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort. *Am J Kidney Dis* 2010;56:896-906.
- Morales E, Valero MA, León M, Hernández E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. *Am J Kidney Dis* 2003;41:319-27.
- Praga M, Morales E. Obesity-related renal damage: changing diet to avoid progression. *Kidney Int* 2010;78:633-5.
- Afshinnia F, Wilt TJ, Duval S, Esmaeili A. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. *Nephrol Dial Transpl* 2010;25:1173-83.
- Poggio ED, Nef PC, Wang X, Greene T, Van Lente F, Dennis VW, et al. Performance of the Cockcroft-Gault and Modification of Diet in

- Renal Disease equations estimating GFR in ill hospitalized patients. *Am J Kidney Dis* 2005;46:242-52.
33. Friedman AN, Strother M, Quinney SK. Measuring of glomerular filtration rate in obese individuals without overt kidney disease. *Nephron Clin Pract* 2010;116:c224-c234.
  34. Ritz E, Koleganova N, Piecha G. Is there an obesity-metabolic related glomerulopathy? *Curr Opin Nephrol Hypert* 2011;20:44-9.
  35. Cohen AH. Massive obesity and the kidney: a morphologic and statistical study. *Am J Pathol* 1975;81:117-30.
  36. Kamlan N, Markowitz GS, Valeri AM. Obesity-related glomerulopathy: an emerging epidemic. *Kidney Int* 2001;51:1498-1509.
  37. Weisinger JR, Kempon RL, Eldridge FL. The nephrotic syndrome: a complication of massive obesity. *Ann Intern Med* 1974;81:440-7.
  38. Wesson DE, Kurtzman NA, Frommer JP. Massive obesity and nephrotic proteinuria with a normal renal biopsy. *Nephron* 1985;40:235-7.
  39. Izzedine H, Coupage M, Reach I. Gastric bypass and resolution of proteinuria in an obese diabetic patient. *Diab Med* 2005;22:1761-2.
  40. Perez G, Devaud N, Escalora A, Downey P. Resolution of early stage diabetic nephropathy in an obese diabetic after gastric bypass. *Obes Surg* 2006;16:1388-91.
  41. Goumeros DS, Kawar B, El Nahas M. Early histologic changes in the kidney of people with morbid obesity. *Nephrol Dial Transpl* 2009;24:3732-8.
  42. Praga M, Hernández E, Morales E, Pérez A, Valero MA, Martínez MA, et al. Clinical features and long-term outcome of obesity associated focal segmental glomerulosclerosis. *Nephrol Dial Transpl* 2001;16:1790-8.
  43. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Prediction of new-onset kidney disease in a community-based hospital. *J Am Med Assoc* 2004;291:844-50.
  44. Iseki K, Ikenuya Y, Kinjo K. Body mass index and the risk of development of end-stage renal disease in a screened cohort. *Kidney Int* 2004;65:1870-9.
  45. Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. *Ann Intern Med* 2006;144:21-8.
  46. Šerblad E, Fored CM, Lindbald P. Obesity and risk for chronic renal failure. *J Am Soc Nephrol* 2006;17:1695-702.
  47. Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthezene F, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. *Am J Kidney Dis* 2001;37:720-7.
  48. Praga M, Hernandez E, Herrero JC, Morales E, Revilla Y, Díaz-González R, et al. Influence of obesity on appearance of proteinuria and renal insufficiency after unilateral nephrectomy. *Kidney Int* 2000;58:2111-8.
  49. Meier-Kriesche H, Andorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. *Transplantation* 2002;73:70-4.
  50. Kramer H, Luke A. Obesity and kidney disease: a big dilemma. *Curr Opin Nephrol Hypertens* 2007;16:237-41.
  51. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. *Am J Clin Nutr* 2005;81:543-54.
  52. DeMutsert R, Snijder MB, Van der Sman-deBeer F. Association of body mass index and mortality is similar in the hemodialysis population at high age and equal duration of follow-up. *J Am Soc Nephrol* 2007;18:967-74.
  53. Wolf G. After all those fat years: renal consequences of obesity. *Nephrol Dial Transplant* 2003;18:2471-4.
  54. Druml W, Metnitz B, Schaden E, Bauer P, Metnitz PG. Impact of body mass on incidence and prognosis of acute kidney injury requiring renal replacement therapy. *Int Care Med* 2010;36:1221-8.
  55. Chudek J, Adamczak M, Nieszporek T. The adipose tissue as a source of vasoactive hormones and cytokines with a potential role in the pathogenesis of cardiovascular and renal diseases. *Rev Port Nephrol Hypert* 2006;20:81-91.
  56. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin role in adrenergic activity. *Hypertension* 2002;39:496-501.
  57. Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, et al. Leptin stimulates proliferation and TGF- $\alpha$  expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. *Kidney Int* 1999;56:860-72.
  58. Sarafadis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. *Am J Nephrol* 2006;26:232-44.
  59. Hunley TE, Ma L, Kon V. Scope and mechanism of obesity-related renal disease. *Curr Opin Nephrol Hypert* 2010;19:227-34.
  60. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: The roles of fetuin-A, adenopectin, and AMPK. *J Am Soc Nephrol* 2010;21:406-12.
  61. Tesauro M, Canale MP, Rodia G. Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines. *Cardio Res Pract* 2011; Article ID 653182.
  62. Teplan V Jr, Vyhnanek F, Guerlich R. Increased proinflammatory cytokine production in adipose tissue of obese patients with chronic kidney disease. *Wien Klin Wochenschr* 2010;122:466-73.
  63. Ruggiero C, Ehrenshaft M, Cleland E, et al. High fat diet induces an initial adaptation of mitochondrial bioenergetics in the kidney despite evident oxidative stress and mitochondrial ROS production. *Am J Physiol Endocrinol Metab* 2011; Mar 8 [Epub ahead of print].
  64. Kanauchi M. Comparison of renal histology between Japanese obese and non-obese microalbuminuric type 2 diabetic patients. *Nephrol Dial Transpl* 2003;18:849-50.
  65. Wesson DE, Simoni J. Acid retention during kidney failure induces endothelin and aldosterone which lead to progressive GFR decline, a situation ameliorated by alkali diet. *Kidney Int* 2010;78:1128-35.